NCT04680637: A reported trial by Amgen
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT04680637 |
|---|---|
| Title | A Phase 2b Dose Ranging Study to Evaluate the Efficacy and Safety of Efavaleukin Alfa in Subjects With Active Systemic Lupus Erythematosus With Inadequate Response to Standard of Care Therapy |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | May 6, 2021 |
| Completion date | May 22, 2023 |
| Required reporting date | May 21, 2024, midnight |
| Actual reporting date | May 21, 2024 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |